Baxalta Inc. has agreed to pay Danish biotechnology company Symphogen A/S up to $1.6 billion for the rights to co-develop six experimental cancer drugs, as it nears a multibillion-dollar takeover deal with Shire PLC.
Deerfield, Ill.-based Baxalta is in advanced talks for Dublin-based Shire to take it over in a deal worth up to $ 32.6 billion, according to a person familiar with the matter, who said an agreement could be announced later this week.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
UK Regulator Investigates Tech Giants’ AI Partnerships Amid Competition Concerns
Apr 24, 2024 by
CPI
TikTok CEO Confident of Overcoming US Ban: ‘We’re Here to Stay’
Apr 24, 2024 by
CPI
EU Conducts First-Ever Raids on a Company Under Foreign Subsidies Regulation
Apr 23, 2024 by
CPI
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI